Skip to content
Screener

Shattuck Labs, Inc. STTK Business Segments — Research and development non-equity compensation

Similar metrics at other companies

Biogen logo
BIIBReportable Segment — Research and development:
$167.1M-0.7%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Research And Development Stock Based Compensation
$19.33M+63.5%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Segment research and development expense
$64.19M-21.1%
Rapid7 logo
RPDReportable Segment — Research and Development Expense, Non-GAAP
$37.83M+2.3%
Zoom Video Communications, Inc. logo
ZMReportable Segment — Adjusted research and development
$153.11M+20.5%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other research and development
$2.91M-7.8%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$694.34M+1,861%
Enterprise value$633.72M-5,344%
P/S694.3×+683×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept sttk:ResearchAndDevelopmentNonEquityCompensation.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
RevenueThree Months Ended June 30, 2026 / $Three Months Ended June 30, 2026 / —Three Months Ended June 30, 2025 / $Three Months Ended June 30, 2025 / —
SL-32514,1072,604
SL-84611,679
Other research and development22,4792,878
Research and development non-equity compensation2,3602,331
Research and development equity compensation1,075867
Total research and development11,7008,680
General and administrative expenses:
General and administrative non-equity compensation1,3971,365

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s business segments — research and development non-equity compensation?
Shattuck Labs, Inc. (STTK) reported business segments — research and development non-equity compensation of $2.36M in Q2 2026.
How has Shattuck Labs, Inc.'s business segments — research and development non-equity compensation changed year-over-year?
Shattuck Labs, Inc.'s business segments — research and development non-equity compensation increased by 1.2% year-over-year, from $2.33M to $2.36M.
What is the long-term trend for Shattuck Labs, Inc.'s business segments — research and development non-equity compensation?
Over 2 years (2023 to 2025), Shattuck Labs, Inc.'s business segments — research and development non-equity compensation has grown at a -28.5% compound annual growth rate (CAGR), from $17.85M to $9.13M.
What does business segments — research and development non-equity compensation mean?
Captures the cash-based salary, bonuses, and benefits paid to personnel directly involved in research and development activities within the reportable segment. Monitoring this expense helps assess the fixed labor costs required to sustain the company's clinical pipeline and scientific innovation.

Ask your AI about Shattuck Labs, Inc.'s business segments — research and development non-equity compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude